Pål Rongved

Image of Pål Rongved
Norwegian version of this page
Phone +47-22855024
Mobile phone +47-95700897
Username
Visiting address Sem Sælands vei 3 Farmasibygningen 0371 OSLO
Postal address Postboks 1068 Blindern 0316 OSLO
Other affiliations School of Pharmacy

Academic Interests

My main interest is related to teaching, research and innovation within organic chemistry related to biological and therapeutic applications.

Present main projects are:

  • Antibiotics and antibacterial resistance: our group has invented a new concept for breaking down antibacterial resistance in several strains of resistant bacteria.
  • New potential drugs against acute myeloid leukaemia (AML): our group has invented new derivatives of the phenazines Iodinin and myxin that has strong effect against human and rat AML cells.
  • Regulators of cystein proteases, especially regulation of zinc. New and innovative zinc-specific fluorescent chelators have been synthesized and are being tested biologically.
  • Regulation of aquaporin (AQP) water channels in relation to brain edema. Some new peptides affecting water diffusion over cell membranes have been constructed and tested.
  • Lipid chemistry: a series of new mimics of hydroxycholesterols have been synthesised and are now being tested biologically. The derivatives are potential new drug candidates with anti-obesity and anti-diabetic activity.
  • We have developed new powder formulations of omega3-rich marine oils that can be used in nutritition and healthcare. The product development is ongoing in our company Omegatri AS http://omegatri.no/ 
  • 5) I worked 21 years in pharmaceutical industry related to medical contrast agents as a scientist, manager and innovator. Thus principles of contrast agents for diagnostic imaging are an area of competence.

Teaching

My teaching at The University of Oslo (UiO) is centred on organic chemistry, medicinal chemistry and innovation, and covers aspects from basic general and organic chemistry to drug chemistry and drug design.

Courses: FRM1000, FRM1010, FRM1030, FRM4010, FRM5210/9210, FRM9905, see http://www.uio.no/studier/program/farm/oppbygging/.

I also do teaching within patenting and innovation.

Higher education and employment history

My CV and career descriptions are available at Linekdin (http://www.linkedin.com).

I hold a cand.scient. from 1981 in organic chemistry at The University of Oslo and a dr. philos from 2000 in medicinal chemistry at the same institution.

Professional carreer :

I was an employee in Nycomed Amersham ASA (now GE Healthcare ASA) for 21 years (23 August 1981 to 1. September 2003). Positions: research scientist, project and department manager. Main focus in GE: early phase innovation with special focus on IPR aspects, and international networking.

In 2003, I was employed by The University of Oslo in two positions:

  • A) Associate professor at School of Pharmacy, Medicinal Chemistry Group. Main focus: teaching, supervising, research and inovation. From June 2005-June 2007: innovation advicer for School of Pharmacy. B) Employee in Birkeland Innovation AS  (now: Inven2 AS), the TTO of UiO.
  • B) Main task in position B: establishment of the TTO at UiO with special focus on innovation advice, organisation of ideas/disclosures of invention (DOFI) and IPR. From 2005-2007, consultant for Birkeland Innovation AS, innovation Advicer.

Personal Innovation achievements: 55 granted US Patents (244 patents with patent family members, gründer in 2 companies, present inventor of 5 projects in collaboration with Inven2 AS. My main goals are to achieve new therapeutic and diagnostic products in research and innovation, and provide high-quality teaching and supervision in medicinal chemistry and related diciplines at School of Pharmacy.

Honoraria

  • DNB Innovation Price in Oslo and Akershus in 2007 for new omega3 powder technology.

Collaboration

  • The collaboration relations are evident from Linkedin and list of publications.

Publications

The list is not exhaustive with respect to patents and patent families.

 

1. Stapling of a 310-Helix with Click Chemistry. Jacobsen, Øyvind;  Maekawa, Hiroaki; Ge, Nien-Hui; Carl Henrik Görbitz; Rongved, Pal; Ottersen, Ole Petter; Amiry-Moghaddam, Mahmood; Klaveness, Jo; Accepted december 2010, Journal of Organic Chemsitry.

 

2. Structural and pharmacological effects of ring-closing metathesis in peptides.

Jacobsen, Oeyvind; Klaveness, Jo; Rongved, Paal; Molecules (2010), 15, 6638-6677.

 

3. Preparation of peptides as aquaporin modulators. Jacobsen, Oyvind; Klaveness, Jo; Rongved, Pal; Amiry-Moghaddam, Mahmood; Ottersen, Ole Petter; Shadidi, Katrine Rese; PCT Int. Appl. (2010), WO 2010073009 A2 20100701.

 

4. Topical cosmetic or pharmaceutical compositions comprising at least one cyclodextrin complex with a marine unsaturated fatty acid. Klaveness, Jo; Rongved, Pal; PCT Int. Appl. (2009), WO 2009136179 A1 20091112.

 

5. Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats. Hoyem, Sverre; Bruheim, Skjalg; Maelandsmo, Gunhild; Standal, Marius; Olberg, Dag Erlend; Brudeli, Bjarne; Aasberg, Anders; Klaveness, Jo; Rongved,

Pal; European Journal of Medicinal Chemistry (2009), 44(10), 3874-3879.

 

6. Synthesis of cyclic peptide analogs of the 310 helical Pro138-Gly144 segment of human aquaporin-4 by olefin metathesis. Jacobsen, Oeyvind; Klaveness, Jo; Petter Ottersen, Ole; Reza Amiry-Moghaddam, Mahmood; Rongved, Paal; Organic & Biomolecular Chemistry (2009), 7(8), 1599-1611.

 

7. Pharmaceutical or nutraceutical tablets. Klaveness, Jo; Brudeli, Bjarne; Rongved, Pal.

From PCT Int. Appl. (2008), WO 2008146016 A2 20081204.

 

8. Treatment of insulin resistance and associated disorders with hydroxycholesterol prodrug derivatives. Kase, Eili Tranheim; Rustan, Arild Chr.; Thoresen, Gunn Hege; Nebb, Hilde Irene; Rongved, Paal; Klaveness, Jo; Brudeli, Bjarne; PCT Int. Appl. (2008), WO 2008041003 A2 20080410

 

9. Water-soluble amino alcohol salts of w-3 and other fatty acids; Rongved, Pal; Klaveness, Jo; PCT Int. Appl. (2007), WO 2007091070 A1 20070816.

 

10. Separation processes. Rongved, Pal; Loevhaug, Dagfinn; Fjerdingstad, Hege; Solbakken, Magne; Godal, Aslak; Cuthbertson, Alan; U.S. Pat. Appl. Publ. (2007), US 20070036722 A1 20070215.

 

11. Synthesis of combretastatins A-1 and B-1. Odlo, Kristin; Klaveness, Jo; Rongved, Pal; Hansen, Trond Vidar; Tetrahedron Letters (2006), 47(7), 1101-1103.

 

12. Synthesis and biological activity of combretastatin derivatives. Odlo, Kristin; Hansen, Trond Vidar; Rongved, Pal; Klaveness, Jo; Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-360.

 

13. Magnetic resonance imaging method and compounds for use in the method. Rongved, Pal; Karlsson, Jan O. g.; Saebo, Karen Briley; PCT Int. Appl. (2004), WO 2004054623 A1 20040701,

 

14. Metal complex compounds.Klaveness, Jo; Rongved, Pal; PCT Int. Appl. (2003), WO 2003045442 A1 20030605.

 

 

15. Contrast agents for the in vivo detection of enzyme activity. Klaveness, Jo; Rongved, Pal; Tolleshaug, Helge; PCT Int. Appl. (2003), WO 2003045441 A1 20030605.

 

17. Diagnostic/therapeutic agents having phospholipid-based microbubbles coupled to one or more vectors. Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Naevestad, Anne; Hellebust, Halldis; Hoff, Lars; Cuthbertson, Alan; Lovhaug, Dagfinn;

Solbakken, Magne; U.S. (2001), US 6261537 B1 20010717.

 

18. Microbubble-containing contrast agents having a non-proteinaceous crosslinked or polymerized amphiphilic shell. Klaveness, Jo; Priebe, Hanno; Rongved, Pangl; Stubberud, Lars; Skurtveit, Roald; Dugstad, Harald; U.S. (2000), US 6106806 A 20000822.

 

19. Preparation of contrast agents based on fatty acids acylated-PEG. Dugstad, Harald; Rongved, Pal; Skurtveit, Roald: U.S. (1999), US 5990263 A 19991123.

 

20. Targetable encapsulated gas microbubbles for separation of target material from liquid samples and separation apparatus. Cuthbertson, Alan; Rongved, Pal; Lovhaug, Dagfinn; Fjerdingstad, Hege; Solbakken, Magne; Godal, Aslak; PCT Int. Appl. (1999), WO 9955837 A2 19991104.

 

21. Ultrasound imaging contrast agents, particularly for perfusion in the myocardium. Eriksen, Morten; Tolleshaug, Helge; Skurtveit, Roald; Cuthbertson, Alan; Ostensen, Jonny; Frigstad, Sigmund; Rongved, Pal; PCT Int. Appl. (1999), WO 9953963 A1 19991028.

 

22. Use of particulate contrast agents in diagnostic imaging for studying physiological parameters. Fossheim, Sigrid Lise; Klaveness, Jo; Bjornerud, Atle; Rongved, Pal; Golman, Klaes; Skurtveit, Roald; PCT Int. Appl. (1999), WO 9952505 A1 19991021.

 

23. Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug. Eriksen, Morten; Ostensen, Jonny; Frigstad, Sigmund; Rongved, Pal; PCT Int. Appl. (1999), WO 9920312 A1 19990429.

 

24. Method using a manganese complex to detect myocardial ischemia and assess myocardial viability. Watson, Alan; Wendland, Michael; Jynge, Per; Karlsson, Jan Olof; Brurok, Heidi; Rongved, Pal; Saeed, Maythem; PCT Int. Appl. (1999), WO 9901162 A2 19990114.

 

25. Methods of photoacoustic imaging. Henrichs, Paul Mark; Eriksen, Marten; Rongved, Pal; Gunther, Wolfgang Hans Heinrich; Snow, Robert Allen; Hollister, Kenneth Robert; McIntire, Gregory Lynn; PCT Int. Appl. (1998), WO 9857667 A1 19981223.

 

26. Contrasts agents comprising an azeotropic mixture of two gases for ultrasound investigations. Klaveness, Jo; Skurtveit, Roald; Rongved, Pal; Hoff, Lars

From PCT Int. Appl. (1998), WO 9847540 A1 19981029

 

27. Preparation of targetable diagnostic and therapeutic gas-contg. or gas-generating ultrasound contrast agents. Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Naevestad, Anne;  PCT Int. Appl. (1998), WO 9818501 A2 19980507

 

28. Preparation of targetable diagnostic and therapeutic gas-contg. or gas-generating ultrasound contrast agents. Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Cuthbertson, Alan; et al. PCT Int. Appl. (1998), WO 9818500 A2 19980507.

.

29. Preparation of targetable diagnostic and therapeutic ultrasound contrast agents. Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Godal, Aslak; Cuthbertson, Alan; et al. PCT Int. Appl. (1998), WO 9818498 A2 19980507.

 

30. Preparation of targetable diagnostic and therapeutic gas-contg. or gas-generating ultrasound contrast agents. Klaveness, Jo; Rongved, Pal; Hogset, Anders; Tolleshaug, Helge; Godal, Aslak; et al. PCT Int. Appl. (1998), WO 9818495 A2 19980507.

 

31. Contrast agents for ultrasonic visualization using an injectable gas dispersion and a diffusible component that can increase gas bubble size in vivo. Ostensen, Jonny; Eriksen, Morten; Frigstad, Sigmund; Rongved, Pal; PCT Int. Appl. (1998), WO 9817324 A2 19980430.

 

32. Improvements in or relating to contrast agents. Johnson, David; Ostensen, Jonny; Eriksen, Morten; Tornes, Audun; Frigstad, Sigmund; Dugstad, Harald; Klaveness, Jo; Rongved, Pal; Skurtveit, Roald; Braenden, Jorunn; PCT Int. Appl. (1998), WO 9805364 A2 19980212.

 

33. Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons. Klaveness, Jo; Rongved, Pal; Solberg, Jan; Strande, Per; Wiggen, Unni Nordby; Redford, Keith; U.S. (1997), US 5674468 A 19971007.

 

34. Improvements in or relating to contrast agents. Dugstad, Harald; Klaveness, Jo; Rongved, Pal; Skurtveit, Roald; Braenden, Jorun; PCT Int. Appl. (1997), WO 9729783 A1 19970821.

 

35. Starch microspheres as carriers for x-ray imaging contrast agents: synthesis and stability of new amino-acid linker Derivatives. Rongved, Paal; Klaveness, Jo; Strande, Per; Carbohydrate Research (1997), 297(4), 325-331.

 

36. Improvements in or relating to contrast agents. Dugstad, Harald; Klaveness, Jo; Rongved, Paal; Skurtveit, Roald; PCT Int. Appl. (1996), WO 9640275 A1 19961219.

 

37. Particulate contrast media for in vivo imaging based on light transmission or reflection. Klaveness, Jo; Fuglaas, Bjorn; Rongved, Paal; Johannesen, Edvin; Henrichs, Paul Mark; Gunther, Wolfgang Hans Heinrich; Bacon, Edward Richard; Toner, John Luke; McIntire, Gregory Lynn; PCT Int. Appl. (1996), WO 9623524 A1 19960808.

 

38. Preparation of aminopolycarboxylic acids and their derivatives as diagnostic and therapeutic agents. Berg, Arne; Almen, Torsten; Klaveness, Jo; Rongved, Pal; Thomassen, Terje; Dugstad, Harald; U.S. (1996), US 5531978 A 19960702.

 

39. Polysaccharides as carriers for magnetic resonance imaging contrast agents: synthesis and stability of a new amino acid linker derivative. Rongved, Paal; Fritzell, Tone Hauk; Strande, Per; Klaveness, Jo; Carbohydrate Research (1996), 287(1), 77-89.

 

40. Contrast agents comprising gas-containing polymer microparticles and/or microballoons for diagnostic applications. Klaveness, Jo; Rongved, Paal; Strande, Per; PCT Int. Appl. (1996), WO 9607434 A1 19960314.

 

41. Contrast medium composition containing manganese. Golman, Klaes; Pettersson, Goeran; Berg, Arne; Klaveness, Jo; Rongved, Paal; Leander, Peter; Leunbach, Ib; Gunther, Wolfgang; PCT Int. Appl. (1996), WO 9605867 A2 19960229.

 

42. Liposomes and a diagnostic composition containing them for humans or animals. Klaveness, Jo; Berg, Arne; Jacobsen, Trond Vegard; Rongved, Paal; Ege, Thorfinn; Kikuchi, Hiroshi; Yachi, Kiyoto; PCT Int. Appl. (1995), WO 9526205 A1 19951005.

 

43. Methylenebis diesters for contrast agents. Dugstad, Harald; Foss, Per Antonius; Klaveness, Jo; Rongved, Paal; Skurtveit, Roald; Solberg, Jan; Aukrust, Inger Reidun Fjeldskaar; PCT Int. Appl. (1995), WO 9521631 A1 19950817.

 

44. Polymer-based gas-containing contrast agent microbubbles encapsulated with non-polymerizable wall-forming block or graft copolymer surfactants and their use in ultrasound imaging. Dugstad, Harald; Foss, Per Antonius; Klaveness, Jo; Redford, Keith; Rongved, Paal; Skurtveit, Roald; Strande, Per; PCT Int. Appl. (1995), WO 9506518 A1 19950309.

 

45. Polymers, biodegradable by enzyme-catalyzed hydrolysis, for medical applications. Solberg, Jan; Strande, Per; Redford, Keith; Rongved, Paal; Klaveness, Jo; Kjemi (1994), 54(8), 26-7.

 

46. Biodegradable organic aerogels for medical use. Berg, Arne; Droege, Michael William; Fellmann, Jere Douglas; Klaveness, Jo; Rongved, Paal; PCT Int. Appl. (1995), WO 9501165 A1 19950112.

 

47. Pharmaceutical liposomes containing contrast agents. Aabye, Arne; Berg, Arne; Dugstad, Harald; Dyvik, Kari; Foss, Per Antonius; Klaveness, Jo; Oestensen, Jonny; Rongved, Paal; Strande, Per; Tolleshaug,

Helge; PCT Int. Appl. (1994), WO 9421302 A1 19940929.

 

48. Oil-in-water emulsions containing contrast agents. Berg, Arne; Dugstad, Harald; Foss, Per Antonius; Klaveness, Jo; Oestensen, Jonny; Rongved, Paal; Strande, Per; PCT Int. Appl. (1994), WO 9421301 A1 19940929.

 

49. Microbubble ultrasound contrast agents. Klaveness, Jo; Rongved, Paal; Johansen, John Henrik; Foss, Per Antonius; Hoegset, Anders; Hvoslef, Anne Marie; PCT Int. Appl. (1994), WO 9406477 A1 19940331.

 

50. Polymer contrast agents for ultrasonic and magnetic resonance imaging. Klaveness, Jo; Redford, Keith; Rongved, Paal; Solberg, Jan; Strande, Per; Wiggen, Unni Nordby; PCT Int. Appl. (1993), WO 9317718 A1 19930916.

 

51. Contrast agents consisting of carbohydrate microparticles. Klaveness, Jo; Rongved, Paal; Stubberud, Lars; PCT Int. Appl. (1993), WO 9313808 A2 19930722.

 

52. Contrast agents consisting of carbohydrate microparticles. Klaveness, Jo; Rongved, Paal; Stubberud, Lars; PCT Int. Appl. (1993), WO 9313809 A1 19930722.

 

53. Contrast agents consisting of carbohydrate particles and amphiphilic carboxylic acids. Klaveness, Jo; Rongved, Paal; Stubberud, Lars; PCT Int. Appl. (1993), WO 9313802 A1 19930722.

 

54. Hydroxamate and hydrazide derivatives of polyamines and their medical use as chelating agents. Himmelsbach, Richard J.; Rongved, Paal; Klaveness, Jo; Strande, Per; Dugstad, Harald; PCT Int. Appl. (1993), WO 9302045 A1 19930204.

 

55. Preparation of acylals and analogs for preparation of biolabile crosslinked ultrasound imaging agents. Holmes, Michael John; Klaveness, Jo; Rongved, Paal; Strande, Per; PCT Int. Appl. (1992), WO 9217213 A1 19921015.

 

56. Gas-encapsulated or gas precursor-encapsulated microbubbles for ultrasound contrast agents, and preparation and polymerization of amphiphiles therefor. Klaveness, Jo; Priebe, Hanno; Rongved, Paal; Stubberud, Lars; PCT Int. Appl. (1992), WO 9217212 A1 19921015.

 

57. Stabilized microparticle ultrasound contrast agents. Klaveness, Jo; Rongved, Paal; Strande, Per; PCT Int. Appl. (1992), WO 9221382 A1 19921210.

 

58. Preparation of acylals and analogs for preparation of biolabile crosslinked imaging agents. Klaveness, Jo; Rongved, Paal; Strande, Per; PCT Int. Appl. (1992), WO 9217436 A1 19921015.

 

59. Preparation of polyazadioto(carboxymethyl)alkanes as medical chelating agents. Strande, Per; Klaveness, Jo; Rongved, Paal; Dugstad, Harald; PCT Int. Appl. (1992), WO 9211232 A1 19920709.

 

60. Multinuclear contrast-enhancing metal complexes for contrast media. Berg, Arne; Almen, Torsten; Krautwurst, Klaus Dieter; Kim, Sook Hui; Rongved, Paal; Klaveness, Jo; Dugstad, Harald; PCT Int. Appl. (1991), WO 9114460 A1 19911003.

 

61. Preparation of chelating agents for use as therapeutic, diagnostic and detoxification agents. Rongved, Paal; Klaveness, Jo; Dugstad, Harald; From PCT Int. Appl. (1991), WO 9115466 A2 19911017.

 

62. Preparation of biological aminopolycarboxylic acid chelating agents. Rongved, Paal; Klaveness, Jo; Dugstad, Harald; PCT Int. Appl. (1991), WO 9115467 A1 19911017.

 

63. Crosslinked, degradable starch microspheres as carriers of paramagnetic contrast agents for magnetic resonance imaging: synthesis, degradation, and relaxation properties. Rongved, Pael; Lindberg, Bernt; Klaveness, Jo; Carbohydrate Research (1991), 214(2), 325-30.

 

64. Water-soluble polysaccharides as carriers of paramagnetic contrast agents for magnetic resonance imaging: synthesis and relaxation properties. Rongved, Paal; Klaveness, Jo; Carbohydrate Research (1991), 214(2), 315-23.

 

65. Preparation of 3,6,9,15-tetraazabicyclo[9.3.1]pentadecane chelating compounds. Klaveness, Jo; Rongved, Paal; Berg, Arne; PCT Int. Appl. (1991), WO 9110669 A1 19910725.

 

66. Chelating agent derivatives. Almen, Torsten; Berg, Arne; Klaveness, Jo; Rongved, Paal; PCT Int. Appl. (1990), WO 9008134 A1 19900726.

 

67. Preparation of heterocyclic medical chelating agents and chelates. Almen, Torsten; Berg, Arne; Dugstad, Harald; Klaveness, Jo; Krautwurst, Klaus Dieter; Rongved, Pal; PCT Int. Appl. (1990), WO 9008138 A1 19900726.

 

68. Evaluation of gadolinium-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. Wang, Shih Chang; Wikstroem, Mats G.; White, David L.; Klaveness, Jo; Holtz, Eckhardt; Rongved, Paul; Moseley, Michael E.; Brasch, Robert C; Radiology (Oak Brook, IL, United States) (1990), 175(2), 483-8.

 

69. Diagnostic and therapeutic paramagnetic compounds and their preparation. Klaveness, Jo; Rongved, Pal; Strande, Per; Eur. Pat. Appl. (1989), EP 326226 A1 19890802.

 

70. Preparation of chelates of aminopolycarboxylates as therapeutic and diagnostic agents. Berg, Arne; Almen, Torsten; Thomassen, Terje; Klaveness, Jo; Rongved, Pal; Eur. Pat. Appl. (1989), EP 299795 A2 19890118.

 

71. A convenient method for the preparation of bicyclic dihydro-1,4-dioxins, dihydro-1,4-oxathiins, dihydro-1,4-dithiins and related compounds. Fjeldskaar, Inger Reidun; Rongved, Paul; Skatteboel, Lars; Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1987), B41(7), 477-86.

 

72. The synthesis of (Z)-8-dodecen-1-ol and its acetate, pheromone components of the Oriental fruit moth (Grapholita molesta). Aukrust, Audun; Rongved, Paal; Skatteboel, Lars; Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1985), B39(4), 267-72.

 

73. Investigation of lanthanide-based starch particles as a model system for liver contrast agents. Fossheim S L; Kellar K E; Mansson S; Colet J M; Rongved P; Fahlvik A K; Klaveness J; Journal of magnetic resonance imaging : JMRI (1999), 9(2), 295-303.

 

74. Low molecular weight lanthanide contrast agents: in vitro studies of mechanisms of action. Fossheim S; Saebo K B; Fahlvik A K; Rongved P; Klaveness J; Journal of magnetic resonance imaging : JMRI (1997), 7(1), 251-7.

 

Published Nov. 3, 2010 3:43 PM - Last modified Oct. 20, 2015 1:59 PM

Projects

No ongoing projects